€25M annual revenueStrategic acquisitionHealthcare & Life Sciences
Alfasigma takes back China operations of its injectable vascular brand
Italian drugmaker Alfasigma signed a business transfer agreement with Hong Kong Ease Comfort Medical Investment Management under which promotion and management of its 伟素 injection in China will return to Alfasigma China. The partner built about a 9% market share, making China the product's largest market. Alfasigma expects about €25 million in incremental annual revenue.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Following healthcare M&A?
The day's biggest deals, healthcare included, in one five-minute email every morning. Built for dealmakers and investors. Free, with no paywalled links.
See what you get →